SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Meletis Konstantinos)
 

Sökning: WFRF:(Meletis Konstantinos) > Elevated circulatin...

  • Terpos, EvangelosGreek Myeloma Study Group, Greece (författare)

Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: Reduction post-bortezomib monotherapy

  • Artikel/kapitelEngelska2011

Förlag, utgivningsår, omfång ...

  • 2011-12-21
  • John Wiley & Sons,2011
  • printrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:liu-192996
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-192996URI
  • https://doi.org/10.1002/ijc.27342DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Sclerostin is a Wingless and Int-1 inhibitor, which is produced by osteocytes and inhibits osteoblast-driven bone formation. Sclerostin is implicated in the pathogenesis of bone loss in metabolic bone disorders but there is no information for its effect on multiple myeloma (MM)-related osteolytic disease. We evaluated circulating sclerostin in 157 newly diagnosed patients with symptomatic myeloma, in 25 with relapsed myeloma who received bortezomib monotherapy, in 21 patients with monoclonal gammopathy of undetermined significance (MGUS), and in 21 healthy controls. Patients with active myeloma had elevated circulating sclerostin compared to MGUS patients and controls (p < 0.01). MM patients who presented with fractures at diagnosis (n = 34) had very high levels of circulating sclerostin compared with all others (p < 0.01), whereas sclerostin correlated negatively with bone specific alkaline phosphatase (a bone formation marker; r = -0.541, p < 0.0001) and positively with C-telopeptide of collagen type-1 (a bone resorption marker; r = 0.524, p < 0.0001). Patients with International Staging System (ISS)-3 disease had higher circulating sclerostin compared to ISS-1 and ISS-2 MM (p = 0.001). Furthermore, patients with high sclerostin (upper quartile, n = 40) had a median survival of 27 months versus 98 months of all others (p = 0.031). Relapsed MM patients had higher levels of circulating sclerostin even compared to newly diagnosed patients (p < 0.01). Bortezomib monotherapy resulted in a reduction of sclerostin by almost 50% in both responders and non-responders. These results suggest that patients with active myeloma have elevated circulating sclerostin, which correlated with advanced disease features including severe bone disease. Our study indicates sclerostin as a possible target for the development of novel therapies to enhance osteoblast function in myeloma.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Christoulas, DimitriosGreek Myeloma Study Group, Greece (författare)
  • Katodritou, EiriniGreek Myeloma Study Group, Greece (författare)
  • Bratengeier, CorneliaBiomarker Design Forschungs GmbH, Vienna, Austria(Swepub:liu)corbr78 (författare)
  • Gkotzamanidou, MariaGreek Myeloma Study Group, Greece (författare)
  • Michalis, EurydikiGreek Myeloma Study Group, Greece (författare)
  • Delimpasi, SosanaGreek Myeloma Study Group, Greece (författare)
  • Pouli, AnastasiaGreek Myeloma Study Group, Greece (författare)
  • Meletis, JohnGreek Myeloma Study Group, Greece (författare)
  • Kastritis, EfstathiosGreek Myeloma Study Group, Greece (författare)
  • Zervas, KonstantinosGreek Myeloma Study Group, Greece (författare)
  • Dimopoulos, Meletios A.Greek Myeloma Study Group, Greece (författare)
  • Greek Myeloma Study Group, GreeceBiomarker Design Forschungs GmbH, Vienna, Austria (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:International Journal of Cancer: John Wiley & Sons131:6, s. 1466-14710020-71361097-0215

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy